Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 1/20 | 0.44 |
| ▸ | MAOA | P21397 | 1/20 | 0.43 |
| ▸ | TLR8 | Q9NR97 | 7/20 | 0.41 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | GPR84 | Q9NQS5 | 2/20 | 0.40 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.40 |
| ▸ | HRH1 | P35367 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7812138 | 0.94 | MAOA (0.48) | HTR2AMAOATLR8PTGS2CYP3A4 | |
| SCHEMBL12075817 | 0.89 | TAAR1 (0.52) | HTR2AMAOATLR8PTGS2CYP3A4 | |
| SCHEMBL12075818 | 0.88 | MAOA (0.43) | HTR2AMAOATLR8PTGS2CYP3A4 | |
| SCHEMBL17277406 | 0.86 | HTR2A (0.42) | HTR2AMAOATLR8PTGS2CYP3A4 | |
| SCHEMBL12062435 | 0.86 | MAOA (0.42) | HTR2AMAOATLR8PTGS2CYP3A4 | |
| SCHEMBL12075819 | 0.85 | MAOA (0.38) | HTR2AMAOATLR8PTGS2CYP3A4 | |
| SCHEMBL12075862 | 0.84 | MAOA (0.41) | HTR2AMAOATLR8PTGS2CYP3A4 | |
| SCHEMBL12075878 | 0.84 | MAOA (0.41) | HTR2AMAOATLR8PTGS2CYP3A4 | |
| SCHEMBL12075485 | 0.84 | MAOA (0.41) | HTR2AMAOATLR8PTGS2CYP3A4 | |
| SCHEMBL17277559 | 0.84 | MAOA (0.41) | HTR2AMAOATLR8PTGS2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9193731-B2 | Antimicrobial compounds and methods of making and using the same | MELINTA THERAPEUTICS, INC. (US) | 2015-11-24 | — | — | US | disclosed |
| US-20120220566-A1 | Antimicrobial Compounds and Methods of Making and Using the Same | RIB-X PHARMACEUTICALS, INC. (US) | 2012-08-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120220566-A1 | Antimicrobial Compounds and Methods of Making and Using the Same | MPO, LPO, CAT | HTR2A 4773/4885MAOA 693/4885TLR8 444/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.